Ligand Pharmaceuticals Incorporated (LGND) - Total Liabilities
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has total liabilities worth $534.78 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LGND net assets growth trend to track the company's year-over-year net asset growth rate.
Ligand Pharmaceuticals Incorporated - Total Liabilities Trend (1994–2025)
This chart illustrates how Ligand Pharmaceuticals Incorporated's total liabilities have evolved over time, based on quarterly financial data. See LGND free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Ligand Pharmaceuticals Incorporated Competitors by Total Liabilities
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chemours Co
NYSE:CC
|
USA | $7.27 Billion |
|
Kaiser Aluminum Corporation
NASDAQ:KALU
|
USA | $1.91 Billion |
|
Shenzhen Gas Corp Ltd
SHG:601139
|
China | CN¥28.16 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥1.18 Billion |
|
China International Marine Containers Group Ltd
SHE:000039
|
China | CN¥100.23 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$5.67 Billion |
|
Cargotec Oyj
HE:CGCBV
|
Finland | €1.46 Billion |
|
OneSpaWorld Holdings Ltd
NASDAQ:OSW
|
USA | $148.13 Million |
Liability Composition Analysis (1994–2025)
This chart breaks down Ligand Pharmaceuticals Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Ligand Pharmaceuticals Incorporated.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ligand Pharmaceuticals Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below shows the annual total liabilities of Ligand Pharmaceuticals Incorporated from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $543.42 Million | +388.10% |
| 2024-12-31 | $111.33 Million | +29.00% |
| 2023-12-31 | $86.30 Million | -47.75% |
| 2022-12-31 | $165.18 Million | -65.33% |
| 2021-12-31 | $476.43 Million | -27.01% |
| 2020-12-31 | $652.76 Million | -10.30% |
| 2019-12-31 | $727.68 Million | +3.97% |
| 2018-12-31 | $699.89 Million | +177.32% |
| 2017-12-31 | $252.37 Million | +9.38% |
| 2016-12-31 | $230.73 Million | +0.52% |
| 2015-12-31 | $229.54 Million | -1.75% |
| 2014-12-31 | $233.62 Million | +323.99% |
| 2013-12-31 | $55.10 Million | -29.15% |
| 2012-12-31 | $77.78 Million | -31.60% |
| 2011-12-31 | $113.70 Million | +37.74% |
| 2010-12-31 | $82.55 Million | -24.92% |
| 2009-12-31 | $109.95 Million | -39.52% |
| 2008-12-31 | $181.81 Million | +26.12% |
| 2007-12-31 | $144.16 Million | -51.74% |
| 2006-12-31 | $298.70 Million | -29.72% |
| 2005-12-31 | $425.04 Million | +4.23% |
| 2004-12-31 | $407.78 Million | +76.89% |
| 2003-12-31 | $230.53 Million | +17.26% |
| 2002-12-31 | $196.59 Million | +12.12% |
| 2001-12-31 | $175.35 Million | +4.04% |
| 2000-12-31 | $168.55 Million | +5.21% |
| 1999-12-31 | $160.20 Million | -4.30% |
| 1998-12-31 | $167.40 Million | +129.00% |
| 1997-12-31 | $73.10 Million | +8.14% |
| 1996-12-31 | $67.60 Million | +3.21% |
| 1995-12-31 | $65.50 Million | +221.08% |
| 1994-12-31 | $20.40 Million | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more